Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEFTAZIDIME Cause Intensive care unit acquired weakness? 33 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Intensive care unit acquired weakness have been filed in association with CEFTAZIDIME (TAZICEF). This represents 1.0% of all adverse event reports for CEFTAZIDIME.

33
Reports of Intensive care unit acquired weakness with CEFTAZIDIME
1.0%
of all CEFTAZIDIME reports
0
Deaths
33
Hospitalizations

How Dangerous Is Intensive care unit acquired weakness From CEFTAZIDIME?

Of the 33 reports, 33 (100.0%) required hospitalization.

Is Intensive care unit acquired weakness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEFTAZIDIME. However, 33 reports have been filed with the FAERS database.

What Other Side Effects Does CEFTAZIDIME Cause?

Drug ineffective (518) Off label use (266) Condition aggravated (228) Septic shock (200) Acute kidney injury (191) Pyrexia (176) Endophthalmitis (128) Multiple organ dysfunction syndrome (124) Neutropenia (123) Drug reaction with eosinophilia and systemic symptoms (121)

What Other Drugs Cause Intensive care unit acquired weakness?

METHYLPREDNISOLONE (57) PROPOFOL (55) MIDAZOLAM (49) PREDNISOLONE (47) PREDNISONE (45) MYCOPHENOLATE MOFETIL (42) THIOPENTAL (41) FENTANYL (40) LEVETIRACETAM (40) VANCOMYCIN (37)

Which CEFTAZIDIME Alternatives Have Lower Intensive care unit acquired weakness Risk?

CEFTAZIDIME vs CEFTIBUTEN CEFTAZIDIME vs CEFTOLOZANE\TAZOBACTAM CEFTAZIDIME vs CEFTRIAXONE CEFTAZIDIME vs CEFTRIAXONE\CEFTRIAXONE CEFTAZIDIME vs CEFUROXIME

Related Pages

CEFTAZIDIME Full Profile All Intensive care unit acquired weakness Reports All Drugs Causing Intensive care unit acquired weakness CEFTAZIDIME Demographics